SecBot SecBot
SECBOTREPLAY Home › Report › TBPH

TBPH · Theravance Biopharma disclosed the planned departure of SVP Development…

Theravance Biopharma, Inc. · 8-K filed Jun 23, 2026 at 17:02 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 23, 2026 at 17:02 ET

Theravance Biopharma disclosed the planned departure of SVP Development and Head of Ireland Office, Dr. ine Miller, effective November 15, 2026, under a compromise agreement tied to the restructuring announced in March 2026. The filing includes a grant of 18,750 RSUs and a $250,000 pension contribution. This is a routine, previously anticipated executive exit with no unexpected C-suite changes.

  • Dr. ine Miller, SVP Development and Head of Ireland Office, will terminate employment on November 15, 2026.
  • Departure is part of the restructuring announced by the company in March 2026.
  • Dr. Miller received a grant of 18,750 restricted share units on June 19, 2026.
  • The company will make a special pension contribution of $250,000 within 30 days of the termination date.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access